M&A Deal Summary

Aspen Pharmacare Acquires GlaxoSmithKline - Arixtra & Fraxiparine/Fraxodi Brands

On September 30, 2013, Aspen Pharmacare acquired life science company GlaxoSmithKline - Arixtra & Fraxiparine/Fraxodi Brands from GSK for 700M GBP

Acquisition Highlights
  • This is Aspen Pharmacare’s 3rd transaction in the Life Science sector.
  • This is Aspen Pharmacare’s 0th largest (disclosed) transaction.
  • This is Aspen Pharmacare’s 1st transaction in the United Kingdom.

M&A Deal Summary
Date 2013-09-30
Target GlaxoSmithKline - Arixtra & Fraxiparine/Fraxodi Brands
Sector Life Science
Buyer(s) Aspen Pharmacare
Sellers(s) GSK
Deal Type Divestiture
Deal Value 700M GBP

Target

GlaxoSmithKline - Arixtra & Fraxiparine/Fraxodi Brands

United Kingdom
GlaxoSmithKline - Arixtra & Fraxiparine/Fraxodi Brands is a specialised sterile production site which manufactures the Brands at Notre Dame de Bondeville, France . Arixtra and Fraxiparine/Fraxodi are made at a sterile site and the ability to manufacture steriles is globally recognised as a specialist activity resulting in limited possible competition. This is a factor further underlined by the increased complexity of the manufacturing process of Fraxiparine/Fraxodi due to the biological nature of the active pharmaceutical ingredients (“API”) used in their production.

Search 199,713 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Aspen Pharmacare

Durban, South Africa
Category Company
Founded 1850
Sector Life Science
Employees8,612
Revenue 40.7B ZAR (2023)
DESCRIPTION

Aspen Pharmacare is a provider of specialty, branded, and generic pharmaceuticals, Aspen has an extensive basket of products that provide treatment for a broad spectrum of acute and chronic conditions experienced through all stages of life. The Group continues to increase the number of lives benefitting from its products, reaching more than 150 countries. In line with the Group’s commercial, production and territorial strategies, Aspen has identified thrombosis, anaesthetics, high potency & cytotoxics and infant nutritionals as four therapeutic categories which will get the highest focus based on materiality and future potential. Aspen Pharmacare was founded in 1850 and is based in Durban, South Africa.

DEAL STATS #
Overall 3 of 4
Sector (Life Science) 3 of 3
Type (Divestiture) 3 of 3
Country (United Kingdom) 1 of 1
Year (2013) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2012-08-15 GlaxoSmithKline - 25 Pharmaceutical Products

Australia

GlaxoSmithKline - 25 Pharmaceutical Products comprise long established pharmaceutical brands of proven performance. The main areas of therapeutic treatment of the Products are analgesic, antibiotics, anti-virals and the central nervous system. Other areas covered include anti-nauseant, anti-inflammatory and muscle relaxants. The leading Products are well recognised brands including Amoxil, Augmentin, Imigran, Kapanol, Lamactil, Mesasal, Timentin, Valtrex, Zantac and Zofran.

Buy £172M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2014-10-31 New Zealand New Milk

Auckland, New Zealand

New Zealand New Milk Ltd. is a producer of infant milk formula in Auckland, New Zealand. NZNM is one of a limited number of companies which holds the required endorsements from the Chinese regulatory authorities to produce infant milk formula for this key territory and the investment in NZNM represents another step towards Aspen’s aspirations to enter the Chinese infant milk formula sector,

Buy -

Seller(S) 1

SELLER

GSK

Brentford, United Kingdom
Category Company
Founded 1715
Sector Life Science
Employees70,212
Revenue 30.3B GBP (2023)
DESCRIPTION
Entrance to a GlaxoSmithKline facility in Morristown, New Jersey.
Entrance to a GlaxoSmithKline facility in Morristown, New Jersey.

GSK is a multinational pharmaceutical, biologics, vaccines and consumer healthcare company. GSK was founded in 1715 and is based in Brentford, United Kingdom.

DEAL STATS #
Overall 12 of 24
Sector (Life Science) 9 of 17
Type (Divestiture) 12 of 23
Country (United Kingdom) 5 of 13
Year (2013) 3 of 4
Size (of disclosed) 1 of 9
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-09-30 GSK s Arixtra Fraxiparine brands

United Kingdom

Arixtra and Fraxiparine/Fraxodi are made at a sterile site and the ability to manufacture steriles is globally recognised as a specialist activity resulting in limited possible competition. This is a factor further underlined by the increased complexity of the manufacturing process of Fraxiparine/Fraxodi due to the biological nature of the active pharmaceutical ingredients (“API”) used in their production.

Sell £700M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2013-12-03 Sirtris Pharmaceuticals

Cambridge, Massachusetts, United States

Sirtris Pharmaceuticals is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with ageing, including metabolic diseases such as Type 2 Diabetes. Our drug candidates are designed to mimic certain beneficial health effects of calorie restriction by activation of sirtuins, a recently discovered class of enzymes that the Company believes control the ageing process.

Sell -
Mergr

Product

Company

Legal